vorinostat has been researched along with Genital Neoplasms, Female in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, M | 1 |
| Cao, H | 1 |
| Tao, K | 1 |
| Xiao, B | 1 |
| Chu, Y | 1 |
| Ma, D | 1 |
| Huang, X | 1 |
| Han, Y | 1 |
| Ji, T | 1 |
1 other study available for vorinostat and Genital Neoplasms, Female
| Article | Year |
|---|---|
HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers.
Topics: Animals; CD8-Positive T-Lymphocytes; Female; Genital Neoplasms, Female; Histone Deacetylase Inhibito | 2023 |